glp-1 and gip/glp-1 receptor agonists Dual agonists: New advances for treating type-2 diabetes Alimentary Pharmacology & Therapeutics |
Description
After revolutionizing care for diabetes and weight loss, GLP-1 drugs are being eyed for more
The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls
Reddys Laboratories, shared his thoughts: The launch of Colozo marks a significant milestone in our gastrointestinal portfolio in India and builds on our legacy of introducing novel, first-in-class therapies following the successful launch of BixiBat last year
Compare semaglutide, tirzepatide, and retatrutide head to head
